Company
Vergent
Vergent Bioscience - Tumor Visualization
Also known as Vergent Bioscience Inc
- Business model
- B2B
- Legal name
- Vergent Bioscience Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Vergent Bioscience’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all solid tumor tissue is removed.
Funding snapshot
- Total raised
- $57MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $18.7M2025-10-07
Funding rounds
- Round, 2025
- $18.7M2025-10-07, SEC form D sold, 20 investors
- Round, 2025
- $3.8M2025-02-03, SEC form D sold, 5 investors
- Round, 2022
- $21.5M2022-08-17, SEC form D sold, 27 investors
- Round, 2021
- $1.2M2021-11-08, SEC form D sold, 16 investors
- Round, 2018
- $11.9M2018-05-18, SEC form D sold, 21 investors
Loading relationship preview